Skip to content

Groningen Antithrombin Study

Groningen Antithrombin Study - GRAS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON39175
Enrollment
250
Registered
2013-01-10
Start date
2013-05-15
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

venous thrombosis and pulmonary embolism

Interventions

None listed

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patient who presented with VTE in our hospital, and were also diagnosed with inherited antithrombin deficieny. (Definition: antithrombin deficiency, measured twice, and also found in at least one family member) Their family members Age >= 18 years Written informed consent

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

MeasureTime frame
1. Number of VTE*s, riskfactors for VTE, treatment for VTE 2. Antithrombin antigen and activity levels 3. Genetic mutations in the SERPINC1 gene

Secondary

MeasureTime frame
• To calculate the absolute and relative risk of VTE in patients with antithrombine deficiency, compared with non-deficient family members (update on previous study) • To describe current anti-coagulant therapy and history of effectiveness and safety of anti-coagulant therapy

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)